Soleno Therapeutics (SLNO) Total Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Total Liabilities data on file, last reported at $112.6 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 31.17% year-over-year to $112.6 million in Q1 2026; TTM through Mar 2026 was $112.6 million, a 31.17% increase from a year earlier, with the FY2025 full-year figure at $113.7 million, up 32.44% from the prior year.
• Total Liabilities for Q1 2026 stood at $112.6 million, down from $113.7 million in the prior quarter.
• Over the last five years, Total Liabilities for SLNO reached as high as $113.7 million in Q4 2025 and fell as low as $16.1 million in Q1 2022.
• Historically, Total Liabilities has averaged $49.4 million across 5 years, with a median of $25.5 million in 2024.
• Across the five-year window, Total Liabilities fell 24.97% in 2022 and jumped 294.31% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $16.1 million in 2022, then surged by 43.56% to $23.2 million in 2023, then surged by 270.34% to $85.9 million in 2024, then jumped by 32.44% to $113.7 million in 2025, then dropped by 0.99% to $112.6 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $112.6 million in Q1 2026, $113.7 million in Q4 2025, and $105.1 million in Q3 2025.